Multiple myeloma · 8 regimens
Cost vs Efficacy
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
KD-PACE Variant #01 | — | R 92 538 | 42d | — | — | — | — | — |
KRD-PACE Variant #01 | — | R 29 215 | — | — | — | — | — | — |
VMPT Variant #03 | — | R 19 167 | 42d | — | — | — | — | 2 |
Bortezomib, Thalidomide, Dexamethasone, Panobinostat Variant #01 Partial | — | R 8 564 | 21d | — | — | — | — | — |
Hyper-CVAD N/A - secondary systemic drug | — | R 6 960 | — | — | — | — | — | — |
V-HyperCAD Variant #01 | — | R 3 398 | — | — | — | — | — | — |
DTPACE Variant #01 | — | R 3 061 | 42d | — | — | — | — | — |
DCEP Variant #01 | — | R 1 586 | 28d | — | — | — | — | — |
8 of 8 regimens shown